Brepocitinib Overview & RVT-3101 Update
Batoclimab and IMVT-1402
VTAMA! Psoriasis | Dermavant
(tapinarof) cream 1%
āā Atopic Dermatitis | Dermavant
VTAMA
(tapinarof) cream 1%
RVT-3101 Ulcerative Colitis | New Vant
RVT-3101 Crohn's Diseases | New Vant
BREPOCITINIB Dermatomyositis | Priovant
BREPOCITINIB Systemic Lupus Erythematosus | Priovant
BREPOCITINIB Other Indications | Priovant
Y BATOCLIMAB Myasthenia Gravis | Immunovant
Modality
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Topical
Topical
Biologic
Biologic
Small Molecule
Small Molecule
Small Molecule
Biologic
Y
BATOCLIMAB Thyroid Eye Disease | Immunovant
Y BATOCLIMAB Chronic Inflammatory Demyelinating Polyneuropathy | Immunovant
A
A
Y
BATOCLIMAB Graves' Disease | Immunovant
BATOCLIMAB Warm Autoimmune Hemolytic Anemia | Immunovant
IMVT-1402 Numerous Indications | Immunovant
n NAMILUMAB Sarcoidosis | Kinevant
RVT-2001 Transfusion-Dependent Anemia in Patients with Lower-Risk MDS | Hemavant
roivant
Pipeline reflects both ongoing clinical trials and expected upcoming trials. VTAMA has only received FDA approval for psoriasis, not atopic dermatitis.
Biologic
Biologic
Biologic
Biologic
Biologic
Biologic
Small Molecule
A
Represents registrational or potentially
registrational trials
21
For investor audiences onlyView entire presentation